CTRI/2015/06/005837已完成3 期
A Phase III Bridging study to evaluate Immunogenicity and Safety of a Pentavalent vaccine (DTwP-HepB-Hib) Shan5 (with Shantha pertussis) as compared to the licensed vaccine, Shan5 (with imported pertussis) when administered as three dose primary series at 6-8, 10-12 and 14-16 Weeks of Age in Healthy Indian Infants.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,040
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy Infants of either sex between 42-56 days (6 to 8 weeks) of age on the day of enrollment
- •2.Born at full term of pregnancy (>= 37 weeks) and with a birth weight >= 2.5 kg.
- •3.Informed consent form signed by parent or legally acceptable representative (LAR) as per local requirements.
- •4.Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures.
排除标准
- •An individual fulfilling any of the following criteria is to be excluded from trial enrollment:
- •1.Participation in another clinical trial in the 4 weeks preceding the trial inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
- •2.Receipt of any vaccine in the 4 weeks preceding the first trial vaccination (except BCG, birth dose OPV and birth dose of Hep B vaccine).
- •3.Planned receipt of any other vaccine within the period from 8 days before to 8 days after each trial vaccination except OPV if not given at birth and during National Immunization Day (NID).
- •4.Previous vaccination against the diphtheria, tetanus, pertussis, hepatitis B (except the birth dose of Hep B vaccine) or Haemophilus influenza type b infection with the trial vaccine or another vaccine.
- •5.Past or current receipt of immunoglobulins, blood or blood-derived products or planned administration during the trial.
- •6.Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy since birth; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks since birth).
- •7.History of diphtheria, tetanus, pertussis, hepatitis B, or Haemophilus influenza type b infections (confirmed either clinically, serologically or microbiologically).
- •8.Known personal or maternal history of HIV or hepatitis B seropositivity.
- •9.Known systemic hypersensitivity to any of the vaccine components, or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances.
- •10.Known thrombocytopenia, as reported by the parent/ legally acceptable representative.
- •11.Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contradicting intramuscular vaccination.
- •12.Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion. (Chronic illness may include, but is not limited to, cardiac, renal, autoimmune, hepatic, haematological, genetic disorders, atopic conditions, congenital defects, diabetes, convulsions or encephalopathy etc.).
- •13.Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature >= 100.4 °F or >=38 °C) on the day of inclusion (a prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided).
- •14.Identified as a natural or adopted child of the Investigator, relatives or employee with direct involvement in the proposed study.
- •15.Subject with definite seizure disorder and getting anticonvulsant therapy.
研究者
相似试验
招募中
3 期
Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAIRCT20210620051639N3Bagheiat-allah University of Medical Sciences10,300
进行中（未招募）
1 期
Immunogenicity and safety of GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b (DTPa-IPV/Hib) conjugate vaccine.EUCTR2013-005577-43-Outside-EU/EEAGlaxoSmithKline Biologicals235
进行中（未招募）
不适用
A phase 3 open-label study to evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I: hexavalent vaccine) at 2 and 6 months of age and Pediacel® (pentavalent vaccine) at 4 months of ageHealthy infants greater than or equal to 46 days and less than or equal to 74 days of age on the day of inclusionMedDRA version: 16.0Level: LLTClassification code 10054187Term: Polio immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10069543Term: Hemophilus influenzae type b immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10069593Term: Pertussis immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054180Term: Diphtheria immunizationSystem Organ Class: 100000004865MedDRA version: 16.0Level: LLTClassification code 10054183Term: Tetanus immunizationSystem Organ Class: 100000004865EUCTR2012-004221-25-ESSanofi Pasteur MSD385
进行中（未招募）
1 期
Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccinePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, Pap test abnormalities, and persistent infection caused by humanpapillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,2,000
已完成
3 期
A Study of V503 (Multivalent HPV Vaccine) in Preadolescents and Adolescents. This study will evaluate the immunogenicity and tolerability of V503 in preadolescent and adolescent subjects between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.CTRI/2009/091/000767Merck Sharp and Dohme2,800